*** SAVE THE DATE – Friday, March 13, 2026 *** Bioanalysis of Antibody-Drug Conjugates Workshop

Bioanalysis of Antibody-Drug Conjugates (ADCs) Workshop
March 13, 2026

Spring House Innovation Park, PA
An IQ In-person Workshop

BACKGROUND

Bioanalysis of ADCs is uniquely challenging, requiring multiple assays (e.g., total antibody, conjugated antibody, free payload, metabolites, immunogenicity) across preclinical and clinical phases. Current industry practice often “measures everything,” resulting in high costs, excessive time demands, and large sample volumes. The IQ Consortium’s Drug Conjugates Working Group, co-chaired by Faye Vazvaei-Smith (Merck & Co. Inc.) and Wenkui Li (Novartis) is driving consensus on best practices to make ADC bioanalysis more efficient and fit-for-purpose.

PURPOSE OF WORKSHOP

Save the date to join us for a full-day IQ Consortium workshop focused on harmonizing and streamlining bioanalytical practices for Antibody-Drug Conjugates (ADCs), reducing unnecessary complexity and resource use while maintaining scientific rigor and patient safety.

GOAL OF WORKSHOP

Develop clear consensus recommendations on which ADC constituent(s) should be measured—and when—enabling efficient fit-for-purpose bioanalysis across the stages of drug development. This includes alignment on:

• Which analyte(s)/assessment (e.g., total antibody, conjugated antibody, free payload, conjugated payload/metabolites/immunogenicity) are essential at each phase (preclinical, Phase I, pivotal studies, post-approval).
• When there is scientifical justification to start or stop measuring specific constituents.
• How to balance regulatory expectations with operational efficiency.

HIGHLIGHTS

• Plenary: The impact of bioanalysis on ADC development
• IQ Survey results: Current practices and opportunities for streamlining
• FDA participation (invited): Regulatory experience
• Breakout sessions: Practical guidance for “what to measure, when”
• Consensus-building: Drafting the IQ playbook for ADC bioanalysis

Who Should Attend?

• • Bioanalytical, PK, and modeling scientists
  • Clinical pharmacology professionals
  • Regulatory affairs professionals
  • Program strategists and operational leads

Why Attend?

• • Shape industry best practices for ADC bioanalysis
  • Collaborate with leading experts from IQ TALG, CPLG, Statistics LGs, and regulatory agencies (FDA invited)
  • Contribute to a decision framework that reduces unnecessary complexity and resource use
  • Engage in breakout sessions on assay strategy, PK/ER modeling, immunogenicity, and operational streamlining

DATE/TIME

Friday, March 13, 2026
Approx. 9 AM – 5 PM ET

​

IN-PERSON EVENT

This Workshop will be in-person only.

​

WORKSHOP MATERIALS   

​Download our Workshop 1-pager and share with your interested colleagues.
​A draft program will be available here (to be available late January 2026).

​​

REGISTRATION AND FEES

Registration to open in late January 2026.
Note: A nominal fee will be charged to cover event expenses.

​

WORKSHOP LOCATION AND LOGISTICS

Spring House Innovation Park
727 Norristown Rd., Building 1
Lower Gwynedd Township, PA 19002

​More information on logistics and accommodations will be available shortly.

​

QUESTIONS

​​Contact the IQ Secretariat:
✉ [email protected] | 📞 +1 (202) 230-5607

Share LinkedIn Announcement